קטגוריה:Chemical subgroup

×¨×× ×¨×××¢××ª ×©× ×§×× ATC â ×ª×ª-×§×××¦× ×××××ª ×××× ×©××××ª ××ª×¨××¤×

×§××××¨×××ª ××©× ×

××£ ×§××××¨×× ×× ×××× ××ª 200 ×§××××¨×××ª ×××©× × ×××××ª, ××ª×× 929 ××§××××¨×× ××××.

(200 ××§×××××) (200 ×××××)

2

2-amino-1-phenylethanol derivatives - C04AAâ (×¨××§×)

3

3-oxoandrosten-(4) derivatives - G03BAâ (7 ××¤××)

5

5-androstanon-(3) derivatives - G03BBâ (××£ ×××)

A

ACE inhibitors and calcium channel blockers - C09BBâ (2 ××¤××)
ACE inhibitors and diuretics - C09BAâ (4 ××¤××)
ACE inhibitors, plain - C09AAâ (37 ××¤××)
Acetic acid derivatives and related substances - M01ABâ (25 ××¤××)
Acid preparations - A09ABâ (2 ××¤××)
Acidifiers - G04BAâ (×¨××§×)
Acridine derivatives - D08AAâ (×¨××§×)
Actinomycines - L01DAâ (×¨××§×)
Adamantane derivatives - N04BBâ (3 ××¤××)
Adrenergic and dopaminergic agents - C01CAâ (26 ××¤××)
Adrenergics and other drugs for obstructive airway diseases - R03AKâ (16 ××¤××)
Adrenergics and other drugs for obstructive airway diseases - R03CKâ (×¨××§×)
Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids - R03ALâ (9 ××¤××)
Adrenocorticotropic hormone - H01AAâ (××£ ×××)
Agents for dermatitis, excluding corticosteroids - D11AHâ (9 ××¤××)
Aldehydes and derivatives - N05CCâ (×¨××§×)
Aldose reductase inhibitors - A10XAâ (×¨××§×)
Aldosterone antagonists - C03DAâ (9 ××¤××)
Alkaloids, excluding rauwolfia - C02KAâ (×¨××§×)
Alkaloids, excluding rauwolfia, in combination with diuretics - C02LKâ (×¨××§×)
Alkyl sulfonates - L01ABâ (3 ××¤××)
Allergen extracts - V01AAâ (9 ××¤××)
Alpha and beta blocking agents - C07AGâ (9 ××¤××)
Alpha and beta blocking agents and other diuretics - C07CGâ (×¨××§×)
Alpha and beta blocking agents and thiazides - C07BGâ (×¨××§×)
Alpha glucosidase inhibitors - A10BFâ (4 ××¤××)
Alpha- and beta-adrenoreceptor agonists - R03AAâ (××£ ×××)
Alpha- and beta-adrenoreceptor agonists - R03CAâ (×¨××§×)
Alpha-adrenoreceptor antagonists - C02CAâ (11 ××¤××)
Alpha-adrenoreceptor antagonists - G04CAâ (30 ××¤××)
Alpha-adrenoreceptor antagonists and diuretics - C02LEâ (×¨××§×)
Aluminium agents - D08ABâ (×¨××§×)
Aluminium compounds - A02ABâ (2 ××¤××)
Amides - N01BBâ (63 ××¤××)
Amino acids - B02AAâ (4 ××¤××)
Amino acids - B05XBâ (××£ ×××)
Amino acids and derivatives - A16AAâ (6 ××¤××)
Amino acids, including combinations with polypeptides - V06DDâ (×¨××§×)
Amino acids/carbohydrates/minerals/vitamins, combinations - V06DEâ (×¨××§×)
Aminoalkyl ethers - R06AAâ (9 ××¤××)
Aminoquinolines - P01BAâ (××£ ×××)
Aminosalicylic acid and derivatives - J04AAâ (×¨××§×)
Aminosalicylic acid and similar agents - A07ECâ (23 ××¤××)
Amphenicols - J01BAâ (××£ ×××)
Analgesics and anesthetics - S02DAâ (2 ××¤××)
Anaplastic lymphoma kinase (ALK) inhibitors - L01EDâ (8 ××¤××)
Androgen, progestogen and estrogen in combination - G03EBâ (×¨××§×)
Androgens and estrogens - G03EAâ (××£ ×××)
Androgens and female sex hormones in combination with other drugs - G03EKâ (×¨××§×)
Androgens for topical use - D11AEâ (×¨××§×)
Androstan derivatives - A14AAâ (×¨××§×)
Anesthetics for topical use - D04ABâ (16 ××¤××)
Anesthetics, local - R02ADâ (16 ××¤××)
Angiotensin II antagonists and calcium channel blockers - C09DBâ (3 ××¤××)
Angiotensin II antagonists and diuretics - C09DAâ (9 ××¤××)
Angiotensin II antagonists, other combinations - C09DXâ (6 ××¤××)
Angiotensin II antagonists, plain - C09CAâ (51 ××¤××)
Anilides - N02BEâ (90 ××¤××)
Antacids with antiflatulents - A02AFâ (××£ ×××)
Antacids with antispasmodics - A02AGâ (×¨××§×)
Antacids with sodium bicarbonate - A02AHâ (×¨××§×)
Antacids, other combinations - A02AXâ (×¨××§×)
Anthracyclines and related substances - L01DBâ (16 ××¤××)
Anthrax vaccines - J07ACâ (×¨××§×)

A (×××©×)

Anti-androgens - L02BBâ (21 ××¤××)
Anti-estrogens - L02BAâ (10 ××¤××)
Anti-gonadotropin-releasing hormones - H01CCâ (10 ××¤××)
Anti-infectives - S02AAâ (4 ××¤××)
Anti-infectives - S03AAâ (7 ××¤××)
Anti-infectives and antiseptics for local oral treatment - A01ABâ (14 ××¤××)
Anti-infectives for treatment of acne - D10AFâ (12 ××¤××)
Anti-inflammatory agents, non-steroids - S01BCâ (10 ××¤××)
Anti-inflammatory agents, non-steroids and anti-infectives in combination - S01CCâ (×¨××§×)
Anti-inflammatory preparations, non-steroids for topical use - M02AAâ (37 ××¤××)
Anti-inflammatory products for vaginal administration - G02CCâ (2 ××¤××)
Anti-inflammatory/antirheumatic agents in combination with corticosteroids - M01BAâ (×¨××§×)
Antiallergic agents, excluding corticosteroids - A07EBâ (×¨××§×)
Antiallergic agents, excluding corticosteroids - R01ACâ (4 ××¤××)
Antiallergic agents, excluding corticosteroids - R03BCâ (×¨××§×)
Antiandrogens and estrogens - G03HBâ (3 ××¤××)
Antiandrogens, plain - G03HAâ (2 ××¤××)
Antiarrhythmics, class Ia - C01BAâ (4 ××¤××)
Antiarrhythmics, class Ib - C01BBâ (3 ××¤××)
Antiarrhythmics, class Ic - C01BCâ (10 ××¤××)
Antiarrhythmics, class III - C01BDâ (7 ××¤××)
Antibiotics - A07AAâ (14 ××¤××)
Antibiotics - C05ABâ (×¨××§×)
Antibiotics - D01AAâ (×¨××§×)
Antibiotics - G01AAâ (3 ××¤××)
Antibiotics - J02AAâ (2 ××¤××)
Antibiotics - J04ABâ (××£ ×××)
Antibiotics - R02ABâ (11 ××¤××)
Antibiotics - S01AAâ (17 ××¤××)
Antibiotics and corticosteroids - G01BAâ (×¨××§×)
Anticholinergics - R03BBâ (12 ××¤××)
Anticholinergics - S01FAâ (3 ××¤××)
Anticholinesterases - N06DAâ (33 ××¤××)
Anticholinesterases - N07AAâ (6 ××¤××)
Anticorticosteroids - H02CAâ (4 ××¤××)
Antidepressants in combination with psycholeptics - N06CAâ (×¨××§×)
Antidiarrheal micro-organisms - A07FAâ (×¨××§×)
Antidotes - V03ABâ (29 ××¤××)
Antifungals for systemic use - D01BAâ (5 ××¤××)
Antigonadotropins and similar agents - G03XAâ (××£ ×××)
Antihidrotics - D11AAâ (×¨××§×)
Antihistamines for topical use - D04AAâ (8 ××¤××)
Antihypertensives for pulmonary arterial hypertension - C02KXâ (28 ××¤××)
Antiinfectives - B05CAâ (×¨××§×)
Antimony compounds - P01CBâ (3 ××¤××)
Antineoplastic cell and gene therapy - L01XLâ (6 ××¤××)
Antineovascularisation agents - S01LAâ (9 ××¤××)
Antiprogestogens - G03XBâ (××£ ×××)
Antipropulsives - A07DAâ (12 ××¤××)
Antiseptics - R02AAâ (18 ××¤××)
Antiseptics and corticosteroids - G01BDâ (×¨××§×)
Antispasmodics in combination with other drugs - A03EDâ (×¨××§×)
Antispasmodics, psycholeptics and analgesics in combination - A03EAâ (×¨××§×)
Antivertigo preparations - N07CAâ (4 ××¤××)
Antiviral monoclonal antibodies - J06BDâ (4 ××¤××)
Antivirals - D06BBâ (18 ××¤××)
Antivirals - S01ADâ (2 ××¤××)
Antivirals for treatment of HCV infections - J05APâ (11 ××¤××)
Antivirals for treatment of HIV infections, combinations - J05ARâ (15 ××¤××)
Antracen derivatives - D05ACâ (5 ××¤××)
Aromatase inhibitors - L02BGâ (20 ××¤××)
Arsenic compounds - G01ABâ (×¨××§×)
Arsenic compounds - P01ARâ (×¨××§×)
Arsenic compounds - P01CDâ (×¨××§×)
Artemisinin and derivatives, combinations - P01BFâ (×¨××§×)
Artemisinin and derivatives, plain - P01BEâ (×¨××§×)
Aryloxyacetic acid derivatives - C03CCâ (×¨××§×)

A (×××©×)

Ascorbic acid (vitamin C), combinations - A11GBâ (×¨××§×)
Ascorbic acid (vitamin C), plain - A11GAâ (×¨××§×)
Avermectines - P02CFâ (×¨××§×)
Azaspirodecanedione derivatives - N05BEâ (××£ ×××)

B

B-Raf serine-threonine kinase (BRAF) inhibitors - L01ECâ (2 ××¤××)
Bacterial and viral vaccines, combined - J07CAâ (12 ××¤××)
Barbiturates and derivatives - N03AAâ (3 ××¤××)
Barbiturates in combination with other drugs - N01AGâ (×¨××§×)
Barbiturates, combinations - N05CBâ (×¨××§×)
Barbiturates, plain - N01AFâ (×¨××§×)
Barbiturates, plain - N05CAâ (2 ××¤××)
Barium sulfate containing X-ray contrast media - V08BAâ (6 ××¤××)
BCR-ABL tyrosine kinase inhibitors - L01EAâ (45 ××¤××)
Belladonna alkaloids, semisynthetic, quaternary ammonium compounds - A03BBâ (×¨××§×)
Belladonna alkaloids, tertiary amines - A03BAâ (11 ××¤××)
Belladonna and derivatives in combination with analgesics - A03DBâ (×¨××§×)
Belladonna and derivatives in combination with psycholeptics - A03CBâ (×¨××§×)
Benzamides - N05ALâ (8 ××¤××)
Benzimidazole derivatives - P02CAâ (3 ××¤××)
Benzodiazepine derivatives - N03AEâ (5 ××¤××)
Benzodiazepine derivatives - N05BAâ (25 ××¤××)
Benzodiazepine derivatives - N05CDâ (13 ××¤××)
Benzodiazepine related drugs - N05CFâ (9 ××¤××)
Benzomorphan derivatives - N02ADâ (×¨××§×)
Benzothiazepine derivatives - C08DBâ (8 ××¤××)
Beta blocking agents - S01EDâ (23 ××¤××)
Beta blocking agents, non-selective - C07AAâ (7 ××¤××)
Beta blocking agents, non-selective, and other antihypertensives - C07FAâ (×¨××§×)
Beta blocking agents, non-selective, and other diuretics - C07CAâ (×¨××§×)
Beta blocking agents, non-selective, and thiazides - C07BAâ (×¨××§×)
Beta blocking agents, non-selective, and vasodilators - C07EAâ (×¨××§×)
Beta blocking agents, non-selective, thiazides and other diuretics - C07DAâ (×¨××§×)
Beta blocking agents, selective - C07ABâ (25 ××¤××)
Beta blocking agents, selective, and other antihypertensives - C07FBâ (×¨××§×)
Beta blocking agents, selective, and other diuretics - C07CBâ (×¨××§×)
Beta blocking agents, selective, and thiazides - C07BBâ (×¨××§×)
Beta blocking agents, selective, and vasodilators - C07EBâ (×¨××§×)
Beta blocking agents, selective, thiazides and other diuretics - C07DBâ (×¨××§×)
Beta-lactamase inhibitors - J01CGâ (10 ××¤××)
Beta-lactamase-resistant penicillins - J01CFâ (4 ××¤××)
Beta-lactamase-sensitive penicillins - J01CEâ (5 ××¤××)
Biguanides - A10BAâ (28 ××¤××)
Biguanides - P01BBâ (2 ××¤××)
Biguanides and amidines - D08ACâ (22 ××¤××)
Bile acid preparations - A05AAâ (7 ××¤××)
Bile acid sequestrants - C10ACâ (2 ××¤××)
Bile acids and derivatives - A05AAâ (3 ××¤××)
Bioflavonoids - C05CAâ (3 ××¤××)
Bismuth preparations - A07BBâ (2 ××¤××)
Bisphosphonates - M05BAâ (36 ××¤××)
Bisphosphonates, combinations - M05BBâ (×¨××§×)
Bisquaternary ammonium compounds - C02BCâ (×¨××§×)
Blood coagulation factors - B02BDâ (106 ××¤××)
Blood substitutes and plasma protein fractions - B05AAâ (18 ××¤××)
Blood tests, auxiliary products - V07ADâ (×¨××§×)
Blood transfusion, auxiliary products - V07ACâ (×¨××§×)
Bone morphogenetic proteins - M05BCâ (×¨××§×)
Boric acid products - D08ADâ (×¨××§×)
Brucellosis vaccines - J07ADâ (×¨××§×)
Bruton's tyrosine kinase (BTK) inhibitors - L01ELâ (11 ××¤××)
Bulk-forming laxatives - A06ACâ (3 ××¤××)
Butylpyrazolidines - M01AAâ (×¨××§×)
Butyrophenone derivatives - N05ADâ (8 ××¤××)

C

Calcineurin inhibitors - L04ADâ (28 ××¤××)
Calcitonin gene-related peptide (CGRP) antagonists - N02CDâ (11 ××¤××)
Calcitonin preparations - H05BAâ (3 ××¤××)

(200 ××§×××××) (200 ×××××)

השינוי האחרון נעשה בֹ־27 בדצמבר 2013 ב־09:35